Table 4 Random-effect single arm subgroup analyses of proportions of HER2 status discordance.
Type of sub-group analyses | HER2 discordance (95% CI) | Population | p-value |
|---|---|---|---|
Method of HER2 detection | |||
IHC3+ defined HER2 positive | 0.06, 95%CI (0.04–0.08) | 532 | 0.172 |
IHC2+ and ISH positive defined HER2 positive | 0.08, 95%CI (0.05–0.12) | 1092 | |
Location | |||
Esophagus | 0.13, 95%CI (0.03–0.44) | 154 | 0.394 |
GEJ/stomach | 0.07, 95%CI (0.05–0.09) | 1470 | |
Histology | |||
Adenocarcinoma | 0.07, 95%CI (0.05–0.10) | 1682 | 0.625 |
Squamous cell carcinoma | 0.04, 95%CI (0.01–0.13) | 148 | |
Type of metastasis | |||
Locoregional lymph node | 0.08, 95%CI (0.06–0.10) | 896 | 0.530 |
Distant metastasis | 0.07, 95%CI (0.04–0.11) | 394 | |
Timing of metastasis | |||
Synchronous | 0.08, 95%CI (0.06–0.10) | 843 | 0.357 |
Metachronous | 0.12, 95%CI (0.04–0.34) | 161 | |
Synchronous and metachronous | 0.05, 95%CI (0.03–0.10) | 548 | |
Type of metastasis and positive conversion | |||
Locoregional lymph node | 0.05, 95%CI (0.03–0.09) | 767 | 0.961 |
Distant metastasis | 0.05, 95%CI (0.03–0.09) | 292 | |
Type of metastasis and negative conversion | |||
Locoregional lymph node | 0.23, 95%CI (0.14–0.35) | 129 | 0.192 |
Distant metastasis | 0.11, 95%CI (0.03–0.29 | 28 | |
Timing of metastasis and positive conversion | |||
Synchronous | 0.06, 95%CI (0.04–0.09) | 755 | 0.216 |
Metachronous | 0.07, 95%CI (0.04–0.13) | 121 | |
Synchronous and metachronous | 0.04, 95%CI (0.03–0.06) | 586 | |
Timing of metastasis and negative conversion | |||
Synchronous | 0.22, 95%CI (0.12–0.36) | 117 | 0.504 |
Metachronous | 0.25, 95%CI (0.01–0.89) | 1 | |
Synchronous and metachronous | 0.12, 95%CI (0.05–0.27) | 63 | |
Sampling type | |||
Surgery | 0.07, 95%CI (0.06–0.10) | 933 | 0.961 |
Biopsy and surgery | 0.05, 95%CI (0.03–0.10) | 691 | |
Received neo-adjuvant therapy | |||
Yes | 0.13, 95%CI (0.03–0.44) | 214 | 0.715 |
No | 0.07, 95%CI (0.05–0.10) | 742 | |
NR | 0.06, 95%CI (0.04–0.11) | 668 | |
Ethnicity | |||
Western | 0.09, 95%CI (0.06–0.13) | 694 | 0.171 |
Asian | 0.06, 95%CI (0.04–0.09) | 930 | |
Study design | |||
Retrospective | 0.07, 95%CI (0.05–0.10) | 1624 | 0.215 |
Prospective | 0.06, 95%CI (0.03–0.12) | 115 | |
